Literature DB >> 28930686

Antibody 27F3 Broadly Targets Influenza A Group 1 and 2 Hemagglutinins through a Further Variation in VH1-69 Antibody Orientation on the HA Stem.

Shanshan Lang1, Jia Xie2, Xueyong Zhu3, Nicholas C Wu3, Richard A Lerner4, Ian A Wilson5.   

Abstract

Antibodies that target both group 1 and group 2 influenza A viruses are valuable for therapeutic and vaccine development, but only a few have been reported to date. Here, we describe a new VH1-69 antibody 27F3 that broadly recognizes heterosubtypic hemagglutinins (HAs) from both group 1 and group 2 influenza A viruses. Structural characterization of 27F3 Fab with A/California/04/2009 (H1N1) hemagglutinin illustrates that 27F3 shares the key binding features observed in other VH1-69 antibodies to the HA stem. Compared to other VH1-69 antibodies, the 27F3 VH domain interacts with the HA stem in a distinct orientation, which alters its epitope and may have influenced its breadth. The diverse rotations of VH1-69 antibodies on the HA stem epitope highlight the different ways that this antibody family can evolve to broadly neutralize influenza A viruses. These results have important implications for understanding how to elicit broad antibody responses against influenza virus.
Copyright © 2017 The Author(s). Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  V(H)1-69; antibody family; broadly neutralizing antibodies; crystal structure; hemagglutinin; influenza virus; phage display

Mesh:

Substances:

Year:  2017        PMID: 28930686      PMCID: PMC5679313          DOI: 10.1016/j.celrep.2017.08.084

Source DB:  PubMed          Journal:  Cell Rep            Impact factor:   9.423


  53 in total

1.  A common solution to group 2 influenza virus neutralization.

Authors:  Robert H E Friesen; Peter S Lee; Esther J M Stoop; Ryan M B Hoffman; Damian C Ekiert; Gira Bhabha; Wenli Yu; Jarek Juraszek; Wouter Koudstaal; Mandy Jongeneelen; Hans J W M Korse; Carla Ophorst; Els C M Brinkman-van der Linden; Mark Throsby; Mark J Kwakkenbos; Arjen Q Bakker; Tim Beaumont; Hergen Spits; Ted Kwaks; Ronald Vogels; Andrew B Ward; Jaap Goudsmit; Ian A Wilson
Journal:  Proc Natl Acad Sci U S A       Date:  2013-12-11       Impact factor: 11.205

2.  The antigenic structure of the influenza virus A/PR/8/34 hemagglutinin (H1 subtype).

Authors:  A J Caton; G G Brownlee; J W Yewdell; W Gerhard
Journal:  Cell       Date:  1982-12       Impact factor: 41.582

3.  Emergence of H7N9 Influenza A Virus Resistant to Neuraminidase Inhibitors in Nonhuman Primates.

Authors:  Yasushi Itoh; Shintaro Shichinohe; Misako Nakayama; Manabu Igarashi; Akihiro Ishii; Hirohito Ishigaki; Hideaki Ishida; Naoko Kitagawa; Takako Sasamura; Masanori Shiohara; Michiko Doi; Hideaki Tsuchiya; Shinichiro Nakamura; Masatoshi Okamatsu; Yoshihiro Sakoda; Hiroshi Kida; Kazumasa Ogasawara
Journal:  Antimicrob Agents Chemother       Date:  2015-06-08       Impact factor: 5.191

4.  Adamantane- and oseltamivir-resistant seasonal A (H1N1) and pandemic A (H1N1) 2009 influenza viruses in Guangdong, China, during 2008 and 2009.

Authors:  Jie Zhou; Lirong Zou; Xin Zhang; Jiazheng Liao; Hanzhong Ni; Nianmei Hou; Yajing Wang; Hui Li; Jie Wu; Marcel Jonges; Adam Meijer; Marion Koopmans; Changwen Ke
Journal:  J Clin Microbiol       Date:  2011-05-18       Impact factor: 5.948

5.  A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins.

Authors:  Davide Corti; Jarrod Voss; Steven J Gamblin; Giosiana Codoni; Annalisa Macagno; David Jarrossay; Sebastien G Vachieri; Debora Pinna; Andrea Minola; Fabrizia Vanzetta; Chiara Silacci; Blanca M Fernandez-Rodriguez; Gloria Agatic; Siro Bianchi; Isabella Giacchetto-Sasselli; Lesley Calder; Federica Sallusto; Patrick Collins; Lesley F Haire; Nigel Temperton; Johannes P M Langedijk; John J Skehel; Antonio Lanzavecchia
Journal:  Science       Date:  2011-07-28       Impact factor: 47.728

6.  Vaccine-Induced Antibodies that Neutralize Group 1 and Group 2 Influenza A Viruses.

Authors:  M Gordon Joyce; Adam K Wheatley; Paul V Thomas; Gwo-Yu Chuang; Cinque Soto; Robert T Bailer; Aliaksandr Druz; Ivelin S Georgiev; Rebecca A Gillespie; Masaru Kanekiyo; Wing-Pui Kong; Kwanyee Leung; Sandeep N Narpala; Madhu S Prabhakaran; Eun Sung Yang; Baoshan Zhang; Yi Zhang; Mangaiarkarasi Asokan; Jeffrey C Boyington; Tatsiana Bylund; Sam Darko; Christopher R Lees; Amy Ransier; Chen-Hsiang Shen; Lingshu Wang; James R Whittle; Xueling Wu; Hadi M Yassine; Celia Santos; Yumiko Matsuoka; Yaroslav Tsybovsky; Ulrich Baxa; James C Mullikin; Kanta Subbarao; Daniel C Douek; Barney S Graham; Richard A Koup; Julie E Ledgerwood; Mario Roederer; Lawrence Shapiro; Peter D Kwong; John R Mascola; Adrian B McDermott
Journal:  Cell       Date:  2016-07-21       Impact factor: 41.582

7.  Antigenic structure of influenza virus haemagglutinin defined by hybridoma antibodies.

Authors:  W Gerhard; J Yewdell; M E Frankel; R Webster
Journal:  Nature       Date:  1981-04-23       Impact factor: 49.962

8.  Oseltamivir-resistant influenza viruses A (H1N1) during 2007-2009 influenza seasons, Japan.

Authors:  Makoto Ujike; Kozue Shimabukuro; Kiku Mochizuki; Masatsugu Obuchi; Tsutomu Kageyama; Masayuki Shirakura; Noriko Kishida; Kazuyo Yamashita; Hiroshi Horikawa; Yumiko Kato; Nobuyuki Fujita; Masato Tashiro; Takato Odagiri
Journal:  Emerg Infect Dis       Date:  2010-06       Impact factor: 6.883

9.  IGHV1-69 polymorphism modulates anti-influenza antibody repertoires, correlates with IGHV utilization shifts and varies by ethnicity.

Authors:  Yuval Avnir; Corey T Watson; Jacob Glanville; Eric C Peterson; Aimee S Tallarico; Andrew S Bennett; Kun Qin; Ying Fu; Chiung-Yu Huang; John H Beigel; Felix Breden; Quan Zhu; Wayne A Marasco
Journal:  Sci Rep       Date:  2016-02-16       Impact factor: 4.379

10.  Structure and Function Analysis of an Antibody Recognizing All Influenza A Subtypes.

Authors:  Nicole L Kallewaard; Davide Corti; Patrick J Collins; Ursula Neu; Josephine M McAuliffe; Ebony Benjamin; Leslie Wachter-Rosati; Frances J Palmer-Hill; Andy Q Yuan; Philip A Walker; Matthias K Vorlaender; Siro Bianchi; Barbara Guarino; Anna De Marco; Fabrizia Vanzetta; Gloria Agatic; Mathilde Foglierini; Debora Pinna; Blanca Fernandez-Rodriguez; Alexander Fruehwirth; Chiara Silacci; Roksana W Ogrodowicz; Stephen R Martin; Federica Sallusto; JoAnn A Suzich; Antonio Lanzavecchia; Qing Zhu; Steven J Gamblin; John J Skehel
Journal:  Cell       Date:  2016-07-21       Impact factor: 41.582

View more
  47 in total

1.  Different genetic barriers for resistance to HA stem antibodies in influenza H3 and H1 viruses.

Authors:  Nicholas C Wu; Andrew J Thompson; Juhye M Lee; Wen Su; Britni M Arlian; Jia Xie; Richard A Lerner; Hui-Ling Yen; Jesse D Bloom; Ian A Wilson
Journal:  Science       Date:  2020-06-19       Impact factor: 47.728

2.  Immunodominance and Antigenic Variation of Influenza Virus Hemagglutinin: Implications for Design of Universal Vaccine Immunogens.

Authors:  Seth J Zost; Nicholas C Wu; Scott E Hensley; Ian A Wilson
Journal:  J Infect Dis       Date:  2019-04-08       Impact factor: 5.226

Review 3.  VH1-69 antiviral broadly neutralizing antibodies: genetics, structures, and relevance to rational vaccine design.

Authors:  Fang Chen; Netanel Tzarum; Ian A Wilson; Mansun Law
Journal:  Curr Opin Virol       Date:  2019-03-16       Impact factor: 7.090

4.  A small-molecule fusion inhibitor of influenza virus is orally active in mice.

Authors:  Maria J P van Dongen; Rameshwar U Kadam; Jarek Juraszek; Edward Lawson; Boerries Brandenburg; Frederike Schmitz; Wim B G Schepens; Bart Stoops; Harry A van Diepen; Mandy Jongeneelen; Chan Tang; Jan Vermond; Alida van Eijgen-Obregoso Real; Sven Blokland; Divita Garg; Wenli Yu; Wouter Goutier; Ellen Lanckacker; Jaco M Klap; Daniëlle C G Peeters; Jin Wu; Christophe Buyck; Tim H M Jonckers; Dirk Roymans; Peter Roevens; Ronald Vogels; Wouter Koudstaal; Robert H E Friesen; Pierre Raboisson; Dashyant Dhanak; Jaap Goudsmit; Ian A Wilson
Journal:  Science       Date:  2019-03-08       Impact factor: 47.728

5.  Preexisting subtype immunodominance shapes memory B cell recall response to influenza vaccination.

Authors:  Rodrigo B Abreu; Greg A Kirchenbaum; Emily F Clutter; Giuseppe A Sautto; Ted M Ross
Journal:  JCI Insight       Date:  2020-01-16

6.  Original antigenic sin priming of influenza virus hemagglutinin stalk antibodies.

Authors:  Claudia P Arevalo; Valerie Le Sage; Marcus J Bolton; Theresa Eilola; Jennifer E Jones; Karen A Kormuth; Eric Nturibi; Angel Balmaseda; Aubree Gordon; Seema S Lakdawala; Scott E Hensley
Journal:  Proc Natl Acad Sci U S A       Date:  2020-07-06       Impact factor: 11.205

7.  A conserved immunogenic and vulnerable site on the coronavirus spike protein delineated by cross-reactive monoclonal antibodies.

Authors:  Chunyan Wang; Rien van Haperen; Javier Gutiérrez-Álvarez; Wentao Li; Nisreen M A Okba; Irina Albulescu; Ivy Widjaja; Brenda van Dieren; Raul Fernandez-Delgado; Isabel Sola; Daniel L Hurdiss; Olalekan Daramola; Frank Grosveld; Frank J M van Kuppeveld; Bart L Haagmans; Luis Enjuanes; Dubravka Drabek; Berend-Jan Bosch
Journal:  Nat Commun       Date:  2021-03-17       Impact factor: 14.919

8.  Passive immunization with influenza haemagglutinin specific monoclonal antibodies.

Authors:  Rajeev Rudraraju; Kanta Subbarao
Journal:  Hum Vaccin Immunother       Date:  2018-07-16       Impact factor: 3.452

Review 9.  Structural insights into the design of novel anti-influenza therapies.

Authors:  Nicholas C Wu; Ian A Wilson
Journal:  Nat Struct Mol Biol       Date:  2018-02-02       Impact factor: 15.369

10.  Canonical features of human antibodies recognizing the influenza hemagglutinin trimer interface.

Authors:  Seth J Zost; Jinhui Dong; Iuliia M Gilchuk; Pavlo Gilchuk; Natalie J Thornburg; Sandhya Bangaru; Nurgun Kose; Jessica A Finn; Robin Bombardi; Cinque Soto; Elaine C Chen; Rachel S Nargi; Rachel E Sutton; Ryan P Irving; Naveenchandra Suryadevara; Jonna B Westover; Robert H Carnahan; Hannah L Turner; Sheng Li; Andrew B Ward; James E Crowe
Journal:  J Clin Invest       Date:  2021-08-02       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.